As of June, 15 Analysts See $-0.89 EPS for Biohaven Pharmaceutical Holding Company Ltd. (BHVN)

May 17, 2018 - By Clyde Turner

On June, 15 Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN)’s earnings release is expected by WallStreet, as reported by RTT. Last year’s EPS was $-1.74, while now analysts expect change of 48.85 % up from current $-0.89 EPS. Last quarter $-0.75 EPS was reported. Analysts forecasts 18.67 % negative EPS growth this quarter. BHVN is reaching $29.95 during the last trading session, after increased 0.60%.Biohaven Pharmaceutical Holding Company Ltd. has volume of 453,190 shares. Since May 17, 2017 BHVN has 0.00% and is . BHVN underperformed by 11.55% the S&P500.

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders.The company has $1.16 billion market cap. The Company’s advanced product candidate includes rimegepant, which is intended to initiate two Phase III clinical trials for the acute treatment of migraine; and trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia.Last it reported negative earnings. The firm also develops BHV-3500 for the prevention of chronic and episodic migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities.

For more Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) news published briefly go to: Prnewswire.com, Seekingalpha.com, Seekingalpha.com, Prnewswire.com or Globenewswire.com. The titles are as follows: “Biohaven Pharmaceuticals Reports First Quarter 2018 Financial and Recent Business Results” published on May 15, 2018, “Biohaven announces secondary endpoint results from Phase 3 clinical trials BHV3000-301 and 302 of Rimegepant” on April 23, 2018, “Biohaven Pharma announces key milestones for 2018” with a publish date: May 15, 2018, “Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients …” and the last “Factors of Influence in 2018, Key Indicators and Opportunity within BIOHAVEN PHARM, WEC Energy Group, Axon …” with publication date: April 19, 2018.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.